Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment
- 858 Downloads
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. The two most common histologic variants are the embryonal and alveolar subtypes. Although successive collaborative group clinical trials have improved survival rates for many RMS patients, the outcome for those patients with metastatic or recurrent disease remains poor. Recent studies have pointed to a possible mesenchymal stem cell as the progenitor for alveolar RMS. Other studies have implicated several cellular mechanisms and pathways being involved in RMS pathogenesis and survival, such as the cyclin-dependent kinase inhibitors, insulin-like growth factor pathway, and the mammalian target of rapamycin pathway, thus providing potential avenues for targeted therapy. Recent clinical trials have tried to improve risk stratification and prediction of clinical outcome based upon clinical or radiographic response to initial therapy and also to determine the role of high-dose chemotherapy with stem cell rescue in high-risk RMS patients.
KeywordsRhabdomyosarcoma Embryonal Alveolar Childhood Sarcoma Stem cell Insulin-like growth factor Rapamycin
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Gurney JG, Young JL, Roffers SD, et al.: Soft tissue sarcomas. In Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. Edited by Ries LAG, Smith MA, Gurney JG, et al. Bethesda, MD: National Cancer Institute SEER Program; 1999:NIH Pub. No. 99–4649.Google Scholar
- 5.Sung L, Anderson JR, Arndt C, et al.: Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Pediatr 2004, 133:666–668.Google Scholar
- 8.Raney RB, Anderson JR, Barr FG, et al.: Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001, 23:215–220.PubMedCrossRefGoogle Scholar
- 10.Arndt CAS, Stoner JA, Hawkins DS, et al.: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s Oncology Group Study D9803. J Clin Oncol 2009, 27:5182–5188.PubMedCrossRefGoogle Scholar
- 13.• Klingebiel T, Boos J, Beske F, et al.: Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high-dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 2008, 50:739–745. This provocative study demonstrates the potential efficacy of low-dose oral therapy versus high-dose therapy with stem cell rescue for high-risk patients. PubMedCrossRefGoogle Scholar
- 18.•• Williamson D, Missiaglia E, de Reynies A, et al.: Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010, 28:2151–2158. This European study demonstrates that fusion gene–negative ARMS has a clinical presentation and genetic expression profile similar to ERMS, which raises the potential question of decreased intensity of therapy for this subset of patients. PubMedCrossRefGoogle Scholar
- 21.Burke M, Anderson JT, Kao SC, et al.: Assessment of response to induction therapy and its influence on 5-year failure-free survival in Group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study IV experience—a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2007, 25:4909–4913.PubMedCrossRefGoogle Scholar
- 22.•• Rodeberg DA, Stoner JA, Hayes-Jordan A, et al.: Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2009, 27:3705–3711. This relevant clinical study demonstrates no relationship between radiographic response and clinical outcome in patients with group III disease. PubMedCrossRefGoogle Scholar
- 27.• Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M: Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett 2009, 279:126–136. This is an excellent review of available data on differentiating the stem cell of origin for alveolar rhabdomyosarcomas.PubMedCrossRefGoogle Scholar